These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 25119181)
1. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Zhang Q; Zhu X; Zhang L; Sun S; Huang J; Lin Y Cancer Chemother Pharmacol; 2014 Oct; 74(4):839-46. PubMed ID: 25119181 [TBL] [Abstract][Full Text] [Related]
2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]. Shi Y; Chen L; Li J; Lü YL; Jiao SC Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593 [TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. Qiu ZQ; Zhao K Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016 [TBL] [Abstract][Full Text] [Related]
5. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer. Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819 [TBL] [Abstract][Full Text] [Related]
6. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408 [TBL] [Abstract][Full Text] [Related]
7. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer. Nie X; Cheng G; Ai B; Zhang S Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080 [TBL] [Abstract][Full Text] [Related]
8. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. Villalobos M; Czapiewski P; Reinmuth N; Fischer JR; Andreas S; Kortsik C; Serke M; Wolf M; Neuser P; Reuss A; Schnabel PA; Thomas M Med Oncol; 2018 Jun; 35(7):106. PubMed ID: 29905882 [TBL] [Abstract][Full Text] [Related]
9. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer]. Zhang L; Liu T; Zhang JQ Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):212-6. PubMed ID: 21575522 [TBL] [Abstract][Full Text] [Related]
10. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606 [TBL] [Abstract][Full Text] [Related]
11. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554 [TBL] [Abstract][Full Text] [Related]
13. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A; Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831 [TBL] [Abstract][Full Text] [Related]
14. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416 [TBL] [Abstract][Full Text] [Related]
15. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer. He YW; Zhao ML; Yang XY; Zeng J; Deng QH; He JX Cancer Chemother Pharmacol; 2015 Apr; 75(4):861-7. PubMed ID: 25732635 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571 [TBL] [Abstract][Full Text] [Related]
18. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322 [TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703). Fukumoto SI; Oizumi S; Harada M; Sukoh N; Nakano K; Fuke S; Sakakibara-Konishi J; Takamura K; Ito K; Fujita Y; Nishigaki Y; Harada T; Akie K; Kinoshita I; Amano T; Isobe H; Dosaka-Akita H; Nishimura M; Cancer Chemother Pharmacol; 2020 Jul; 86(1):117-127. PubMed ID: 32564128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]